Omnicare (NYS: OCR) reported earnings on Oct. 31. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Omnicare missed estimates on revenues and whiffed on earnings per share.
Compared to the prior-year quarter, revenue shrank slightly and GAAP earnings per share grew significantly.
Margins expanded across the board.
Omnicare reported revenue of $1.50 billion. The seven analysts polled by S&P Capital IQ foresaw sales of $1.54 billion on the same basis. GAAP reported sales were 2.8% lower than the prior-year quarter's $1.54 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.65. The eight earnings estimates compiled by S&P Capital IQ anticipated $0.73 per share. GAAP EPS of $0.55 for Q3 were 129% higher than the prior-year quarter's $0.24 per share. (The prior-year quarter included -$0.09 per share in earnings from discontinued operations.)
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 24.7%, 230 basis points better than the prior-year quarter. Operating margin was 8.9%, 40 basis points better than the prior-year quarter. Net margin was 4.1%, 230 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $1.55 billion. On the bottom line, the average EPS estimate is $0.71.
Next year's average estimate for revenue is $6.21 billion. The average EPS estimate is $2.86.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 228 members out of 248 rating the stock outperform, and 20 members rating it underperform. Among 83 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 79 give Omnicare a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Omnicare is outperform, with an average price target of $38.69.
Add Omnicare to My Watchlist.
The article The Gory Details of Omnicare's Earnings Miss originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.